The Readout
One issue a week. Four sections: the catalysts on Bork’s nose, the recalls and CRLs in the doghouse, the approvals worth a treat, and the calendar for the week ahead.
July 5, 2026
It's a slow week in biotech, but I've still managed to dig up some interesting tidbits, including a few companies that are quietly making progress without much fanfare, like $VRTX. With no major disasters or triumphs to report, this issue is all about parsing the subtleties of the industry's steady hum.
read the full issue →A weekly editorial on biotech catalysts.
Every Sunday, Bork synthesizes the catalyst calendar into four sections — Sniff Test (next 30 days, ranked by sponsor reputation × phase weight × proximity), Doghouse (CRLs, recalls, missed endpoints), Good Boy (approvals, positive readouts), and The Barrel (everything else this week worth tracking).
Generated from pharmadog's own database — the same 35,000+ catalysts pulled from FDA, ClinicalTrials.gov, SEC EDGAR, and biotech RSS you can browse interactively. Every claim links back to its source row. No paywall. Free archive.
- Jun 14June 14, 2026It's a quiet week in biotech, with no companies landing in the doghouse or getting a good boy nod, leaving me to dig deeper for interesting tidbits. I'm keeping a close eye on $VRTX, which has been relatively quiet lately, but its cystic fibrosis franchise remains a significant player in the space.
- Jun 7June 7, 2026It's a quiet week in biotech, with no companies landing in the doghouse or getting a gold star, but that's given me a chance to dig into some of the more subtle trends shaping the industry. With no major sniff tests or breakthroughs to speak of, I'm taking a closer look at the underlying currents that will likely influence $IBB and $XBI in the months to come.